K

Keystone Urology Specialists | Lancaster, PA

Research site
(Unclaimed)
Location
2106 Harrisburg Pike, Suite 200, Lancaster, Pennsylvania, United States of America

Site insights

Top conditions

Top treatments

Enzalutamide
Talazoparib
Relugolix
Prednisone
Niraparib
TAR-210
Docetaxel
Leuprolide
Methylprednisolone
Leuprolide Acetate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 12 total trials

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followe...

Enrolling
Bladder Cancer
Urologic Cancer
Other: n-dodecyl-B-D-maltoside
Drug: Cretostimogene Grenadenorepvec

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus predniso...

Active, not recruiting
Metastatic Castration-sensitive Prostate Cancer
Drug: Placebo for Niraparib
Drug: Niraparib

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's ch...

Enrolling
Non-Muscle Invasive Bladder Cancer
Drug: MMC
Drug: Gemcitabine

This study is a multinational Phase 3, randomized, double-blind, non-inferiority, efficacy and safety study of oral HC-1119 (80 mg/day) versus enzalu...

Active, not recruiting
Castration-resistant Prostate Cancer
Prostate Cancer Metastatic
Drug: Enzalutamide
Drug: HC-1119

This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enroll...

Active, not recruiting
Prostate Cancer
Drug: Leuprolide Acetate
Drug: Relugolix

The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radica...

Active, not recruiting
Hormone Sensitive Prostate Cancer
Prostate Cancer
Drug: Enzalutamide
Drug: Placebo (No longer applicable in Open Label study period)

To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-c...

Active, not recruiting
Non Muscle Invasive Bladder Cancer
Biological: CG0070
Biological: Pembrolizumab Injection

The purpose of this study is to establish recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) and preliminary antitumor activity of O...

Enrolling
Neuroendocrine Prostate Cancer
Metastatic Prostate Cancer
Drug: ORIC-944

This study is being conducted to assess the safety and tolerability of relugolix with other agents approved for use in combination with androgen depr...

Active, not recruiting
Metastatic Castration-Resistant Prostate Cancer
Non-Metastatic Castration-Resistant Prostate Cancer
Drug: Abiraterone
Drug: Methylprednisolone

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination...

Active, not recruiting
Prostate Cancer
Drug: Placebo plus enzalutamide
Drug: talazoparib plus enzalutamide

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of tal...

Active, not recruiting
mCRPC
Drug: Talazoparib with enzalutamide
Drug: Placebo with enzalutamide

Trial sponsors

Pfizer logo
C
J
Sumitomo Pharma logo
Bayer logo
H
O

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems